ATAP Letter to Congressional Leaders on Biosimilar Red Tape Elimination Act (S. 2305)

In letters to the Speaker of the U.S. House of Representatives and Senate leadership ATAP sheds light on existing PBM abuses that have prevented biosimilar access. The letter expresses concerns that the Biosimilar Red Tape Elimination Act may exacerbate PBM influence over drug access.

See the full letter here: